Cargando…

The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies

BACKGROUND: Enzyme‐linked immunosorbent assay (ELISA) has traditionally been used to detect myeloperoxidase (MPO) and proteinase 3 (PR3) antibodies, although it is time‐consuming and physically demanding. As a novel and highly effective immunoassay, we compared chemiluminescent immunoassay (CIA) wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Xiuzhu, Liu, Jing, Wang, Tiancheng, Zhou, Jiansuo, Cui, Liyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891508/
https://www.ncbi.nlm.nih.gov/pubmed/33034910
http://dx.doi.org/10.1002/jcla.23615
_version_ 1783652713253306368
author Hou, Xiuzhu
Liu, Jing
Wang, Tiancheng
Zhou, Jiansuo
Cui, Liyan
author_facet Hou, Xiuzhu
Liu, Jing
Wang, Tiancheng
Zhou, Jiansuo
Cui, Liyan
author_sort Hou, Xiuzhu
collection PubMed
description BACKGROUND: Enzyme‐linked immunosorbent assay (ELISA) has traditionally been used to detect myeloperoxidase (MPO) and proteinase 3 (PR3) antibodies, although it is time‐consuming and physically demanding. As a novel and highly effective immunoassay, we compared chemiluminescent immunoassay (CIA) with ELISA to verify the application value of CIA in MPO and PR3 antibodies detection. METHODS: By ELISA and CIA, serum levels of anti‐MPO and anti‐PR3 antibodies were measured in 63 anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis (AAV) patients (AAV group), including 47 microscopic polyangiitis (MPA) patients and 16 granulomatosis with polyangiitis (GPA) patients, in addition, 68 patients in interference control group (IC group), 19 healthy subjects in healthy control group (HC group). We compared MPO and PR3 antibodies levels and positive rates measured by these two methods among groups. Relationship and coincidence rate between ELISA and CIA were investigated. Diagnostic values for clinical outcomes for MPO and PR3 antibodies were assessed by receiver operator characteristic (ROC) curve. RESULTS: In AAV patients, when detecting anti‐MPO (r = .90) and anti‐PR3 (r = .81), CIA was highly correlated with ELISA, companying with highly total (88.89%, 92.06%, respectively) and positive coincidence rates (84.78%, 77.27%, respectively). In HC group, anti‐PR3 positive rate detected by both immunoassay were 0, anti‐MPO almost were 0, which without statistically significant difference (P = .32). In IC group, the total (76.47%, 58.82, respectively) and positive coincidence rates (48.38%, 30.00%, respectively) of anti‐MPO and anti‐PR3 were the lowest, but the negative coincidence rates reached 100%. By CIA, similar to ELISA, the levels of anti‐MPO were significantly higher both in AAV patients (56.00; [4.40‐235.30]) and MPA patients (98.00; [27.90‐324.70]) compared with either IC group (3.20; [3.20‐18.55) (P < .0001) or HC group (3.20; [3.20‐3.20]) (P < .0001), yielded an area under curve (AUC) of 0.76 for AAV and 0.89 for MPA, the concentration of anti‐PR3 in GPA group (66.65; [24.43‐150.00]) was significantly higher than that in IC group (2.3; [2.3‐10.95]) (P < .0001) and HC group (2.3; [2.3‐2.3]) (P < .0001), with an AUC of 0.92. CONCLUSION: Similar to ELISA, CIA was competent to detect MPO and PR3 antibodies in AAV patients and healthy population, thus distinguish AAV patients from IC group and HC group and effectively diagnose MPA and GPA.
format Online
Article
Text
id pubmed-7891508
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78915082021-03-10 The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies Hou, Xiuzhu Liu, Jing Wang, Tiancheng Zhou, Jiansuo Cui, Liyan J Clin Lab Anal Research Article BACKGROUND: Enzyme‐linked immunosorbent assay (ELISA) has traditionally been used to detect myeloperoxidase (MPO) and proteinase 3 (PR3) antibodies, although it is time‐consuming and physically demanding. As a novel and highly effective immunoassay, we compared chemiluminescent immunoassay (CIA) with ELISA to verify the application value of CIA in MPO and PR3 antibodies detection. METHODS: By ELISA and CIA, serum levels of anti‐MPO and anti‐PR3 antibodies were measured in 63 anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis (AAV) patients (AAV group), including 47 microscopic polyangiitis (MPA) patients and 16 granulomatosis with polyangiitis (GPA) patients, in addition, 68 patients in interference control group (IC group), 19 healthy subjects in healthy control group (HC group). We compared MPO and PR3 antibodies levels and positive rates measured by these two methods among groups. Relationship and coincidence rate between ELISA and CIA were investigated. Diagnostic values for clinical outcomes for MPO and PR3 antibodies were assessed by receiver operator characteristic (ROC) curve. RESULTS: In AAV patients, when detecting anti‐MPO (r = .90) and anti‐PR3 (r = .81), CIA was highly correlated with ELISA, companying with highly total (88.89%, 92.06%, respectively) and positive coincidence rates (84.78%, 77.27%, respectively). In HC group, anti‐PR3 positive rate detected by both immunoassay were 0, anti‐MPO almost were 0, which without statistically significant difference (P = .32). In IC group, the total (76.47%, 58.82, respectively) and positive coincidence rates (48.38%, 30.00%, respectively) of anti‐MPO and anti‐PR3 were the lowest, but the negative coincidence rates reached 100%. By CIA, similar to ELISA, the levels of anti‐MPO were significantly higher both in AAV patients (56.00; [4.40‐235.30]) and MPA patients (98.00; [27.90‐324.70]) compared with either IC group (3.20; [3.20‐18.55) (P < .0001) or HC group (3.20; [3.20‐3.20]) (P < .0001), yielded an area under curve (AUC) of 0.76 for AAV and 0.89 for MPA, the concentration of anti‐PR3 in GPA group (66.65; [24.43‐150.00]) was significantly higher than that in IC group (2.3; [2.3‐10.95]) (P < .0001) and HC group (2.3; [2.3‐2.3]) (P < .0001), with an AUC of 0.92. CONCLUSION: Similar to ELISA, CIA was competent to detect MPO and PR3 antibodies in AAV patients and healthy population, thus distinguish AAV patients from IC group and HC group and effectively diagnose MPA and GPA. John Wiley and Sons Inc. 2020-10-09 /pmc/articles/PMC7891508/ /pubmed/33034910 http://dx.doi.org/10.1002/jcla.23615 Text en © 2020 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Article
Hou, Xiuzhu
Liu, Jing
Wang, Tiancheng
Zhou, Jiansuo
Cui, Liyan
The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies
title The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies
title_full The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies
title_fullStr The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies
title_full_unstemmed The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies
title_short The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies
title_sort performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891508/
https://www.ncbi.nlm.nih.gov/pubmed/33034910
http://dx.doi.org/10.1002/jcla.23615
work_keys_str_mv AT houxiuzhu theperformanceofthechemiluminescentimmunoassayformeasuringserummyeloperoxidaseandproteinase3antibodies
AT liujing theperformanceofthechemiluminescentimmunoassayformeasuringserummyeloperoxidaseandproteinase3antibodies
AT wangtiancheng theperformanceofthechemiluminescentimmunoassayformeasuringserummyeloperoxidaseandproteinase3antibodies
AT zhoujiansuo theperformanceofthechemiluminescentimmunoassayformeasuringserummyeloperoxidaseandproteinase3antibodies
AT cuiliyan theperformanceofthechemiluminescentimmunoassayformeasuringserummyeloperoxidaseandproteinase3antibodies
AT houxiuzhu performanceofthechemiluminescentimmunoassayformeasuringserummyeloperoxidaseandproteinase3antibodies
AT liujing performanceofthechemiluminescentimmunoassayformeasuringserummyeloperoxidaseandproteinase3antibodies
AT wangtiancheng performanceofthechemiluminescentimmunoassayformeasuringserummyeloperoxidaseandproteinase3antibodies
AT zhoujiansuo performanceofthechemiluminescentimmunoassayformeasuringserummyeloperoxidaseandproteinase3antibodies
AT cuiliyan performanceofthechemiluminescentimmunoassayformeasuringserummyeloperoxidaseandproteinase3antibodies